BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Dear Doctor Letter (Rote-Hand-Brief) on Maxipime® (cefepime): risk of serious neurologic adverse events in patients with renal impairment

2018.06.18

Active substance: cefepime

Information is circulated on the risk of serious adverse events, including encephalopathy, in patients with renal impairment who received doses that exceeded the recommendations.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 178KB, File is accessible